About

Mitchell D. Creinin, M.D. is a Distinguished Professor and the Director of the Complex Family Planning Fellowship at UC Davis Health within the Department of Obstetrics and Gynecology. He is a board-certified specialist in Obstetrics and Gynecology and a subspecialist in Complex Family Planning. Dr. Creinin has dedicated his career to teaching, research, and clinical care with a focus on ensuring women and their families have full access to reproductive health care. His research concentrates on developing new contraceptive technologies, managing miscarriage, and improving abortion techniques, with an emphasis on enhancing the quality of care available to patients both locally and in lower and middle-income countries.

Research topics

• Medicine
• Internal medicine
• Family medicine
• Endocrinology
• Political Science
• Gynecology
• Pharmacology
• Surgery
• Obstetrics
• Medical emergency
• Nursing
• Environmental health
• Law
• Biology
• Anesthesia

Selected publications

• Understanding U.S. non-religious hospital inpatient approval mechanisms for induced abortion

  Contraception · 2026-01-08

  articleSenior author
  PublisherDOI

• Desire for pregnancy remembrance among patients undergoing procedural uterine evacuation

  Contraception · 2025-12-12

  articleOpen access
  PublisherOA PDFDOI

• Estetrol/Drospirenone safety in a population with cardiovascular risk factors

  Contraception · 2025-02-28 · 9 citations

  article1st authorCorresponding
  PublisherDOI

• Depomedroxyprogesterone acetate impact on mifepristone action during medication abortion

  The European Journal of Contraception & Reproductive Health Care · 2025-05-14

  article1st authorCorresponding

  PURPOSE: To evaluate outcomes by gestational duration in patients who did and did not receive depomedroxyprogesterone acetate (DMPA) concurrently with mifepristone for mifepristone-misoprostol medication abortion and estimate the impact of DMPA on mifepristone action. MATERIALS AND METHODS: In this secondary analysis of a retrospective study, we analysed treatment failure and continuing pregnancy as a reason for failure both overall and by gestational duration group. We assessed available literature to estimate that misoprostol alone would result in abortion in approximately 74% of pregnancies without mifepristone and calculated the impact of adding mifepristone to the treatment regimen and of DMPA on these outcomes. RESULTS: = 0.04) concomitant DMPA administration. No individual gestational duration group demonstrated a significant difference in outcomes between patients that did and did not receive DMPA, likely because of small numbers in each group. Overall, concomitant DMPA with mifepristone increased the likelihood of an ongoing pregnancy by 25.3% of the expected rate if DMPA completely blocked all mifepristone action but only by 16.1% for patients with pregnancies ≤49 days gestation. CONCLUSION: Ongoing pregnancy as the reason for medication abortion failure occurs more frequently with advancing gestation in patients that do and do not receive DMPA concurrently with mifepristone. DMPA may impact mifepristone variably by gestational duration, but larger studies are needed.

  PublisherDOI

• Postpartum Care Recommendations from Parents of Premature Infants Requiring Intensive Care

  Maternal and Child Health Journal · 2025-04-28 · 2 citations

  articleOpen access

  OBJECTIVE: To describe postpartum care preferences and experiences among individuals who deliver a premature infant requiring neonatal intensive care. METHODS: In this qualitative description study, we recruited patients 2 to 8 weeks after delivery of a premature infant requiring neonatal intensive care to participate in semi-structured interviews. We asked participants to share their postpartum care experiences including their expectations and preferences regarding what is addressed during postpartum visits, their decision-making process in attending scheduled postpartum visits, and their suggestions for how to optimize postpartum care to serve their needs. We used thematic analysis to generate codes and identify themes. RESULTS: Of 26 participants, 8 (31%) had attended a postpartum visit, 4 (15%) had missed their appointment, and 14 (54%) had a visit scheduled to occur after the time of the study interview. We found that participants weigh the perceived benefits of attending a postpartum visit against barriers to care, such as insurance restrictions, competing responsibilities and priorities when deciding whether to attend their postpartum visit. At their postpartum visit, participants preferred when clinicians centered the visits around the participants' goals and tailored the encounter to their specific concerns. Lastly, participants recognize that screening for postpartum mood disorders is important; however, the current screening tools do not differentiate between mood disorders and expected responses to a stressful neonatal intensive care experience. CONCLUSIONS FOR PRACTICE: Postpartum visits tailored to patient preferences for care in the early postpartum period are needed alongside system-level interventions to address barriers to accessing postpartum care for patients who deliver premature infants.

  PublisherOA PDFDOI

• EARLY PREGNANCY RHD-IMMUNE GLOBULIN PRACTICE PATTERNS AMONG REI PHYSICIANS AND THE NEED FOR ASRM GUIDELINES FOR RHIG ADMINISTRATION

  Fertility and Sterility · 2025-12-01

  articleSenior author
  PublisherDOI

• Transcervical foley balloon versus osmotic dilators for cervical preparation

  Contraception · 2025-02-12

  letterOpen accessSenior author
  PublisherOA PDFDOI

• Etonogestrel implant failure in a woman taking thyroid hormone replacement: A case report

  Case Reports in Women s Health · 2025-01-18

  articleOpen accessSenior author

  The etonogestrel implant is known to have high contraceptive efficacy for up to 5 years. This case report describes etonogestrel implant failure during year 4 of use in a patient with a normal body mass index. The patient was receiving thyroid hormone replacement after a thyroidectomy and was found to have iatrogenic thyrotoxicosis in the months preceding pregnancy. Further study of the effects of thyroid hormone on etonogestrel metabolism are indicated.

  PublisherDOI

• Errors in the Society of Family Planning medication management for early pregnancy loss clinical recommendations

  Contraception · 2025-11-07

  letterSenior author
  PublisherDOI

• Contraceptive Choices for Premenopausal Women and Breast Cancer Risk

  JAMA Oncology · 2025-10-02

  article

  This Viewpoint explores the injunction against taking hormonal contraceptives among premenopausal women at increased risk for breast cancer.

  PublisherDOI

Frequent coauthors

• Kurt T. Barnhart

  University of Pennsylvania

  440 shared

• Carolyn Westhoff

  Columbia University Irving Medical Center

  344 shared

• Matthew F. Reeves

  282 shared

• Jerry M. Gilles

  Heinrich Heine University Düsseldorf

  277 shared

• Margaret Frederick

  Sinai Hospital

  177 shared

• Jeffrey T. Jensen

  University of Nebraska at Omaha

  171 shared

• Bryna Harwood

  131 shared

• Anne Davis

  128 shared

Education

• M.D., Obstetrics and Gynecology

  University of California, San Francisco

  1991

• B.A., Psychology

  University of California, Berkeley

  1986

Awards & honors

• Richard H. Oi, MD OB/GYN Excellence in Teaching (2016)
• American College of Obstetricians and Gynecologists District…
• UC Davis Medical Center Quality and Safety Committee Physici…
• Contraception Outstanding Article Award (2010, 2015)
• ACOG/Roy M. Pitkin Award (2005, 2007, 2011)